After months of rumous, Audi has unveiled a new EV range in China, sporting, instead of the rings (arguably one of the best ...

IGA score of cleared (0) or minimal disease (1) was achieved by a significantly greater proportion of those in the guselkumab vs placebo group, 74.2% vs 12.4%, respectively. Arexvy is currently ...

I-Mab, a US-based, global, biotech company, exclusively focused on the development of highly differentiated immunotherapies for the treatment of cancer, today announced that management will ...

Trip.com Group's corporate travel management brand, Trip.Biz, recently hosted its annual conference, 'Trip.Biz Transform 2024,' in Singapore. Japan's Travel Management Company (TMC) market is highly ...

WHAT TO WATCH --VACCINES: Investors' concerns linger over sales expectations for the company's respiratory syncytial virus vaccine Arexvy and its best-selling shingles vaccine Shingrix for the ...

We are pleased that AREXVY remains among the vaccines being offered this season, and that older Ontarians will continue to benefit from the protection offered by RSV vaccines." "As a company invested ...

GSK's major growth drivers, Shingrix and Arexvy, along with recent legal progress, make its current undervaluation unjustified, leading to a "Strong Buy" rating. The company’s diversified ...

GSK plc announced new preliminary data for Arexvy (respiratory syncytial virus vaccine, recombinant adjuvanted) in adults aged 18-49 at increased risk for RSV-LRTD due to certain underlying medical ...

Graham Parry has given his Sell rating due to a combination of factors affecting GlaxoSmithKline’s Arexvy vaccine. The challenges highlighted include the limited effectiveness of a single shot ...

Pfizer axed 80 Kansas employees in the second round of cuts this month ... GSK announced a single dose of Arexvy elicited robust immune response with acceptable safety profile in adults aged 18-49 at ...

US pharma major GSK (LSE: GSK) yesterday announced new preliminary data for Arexvy (respiratory syncytial virus vaccine, recombinant adjuvanted) in adults aged 18-49 at increased risk for RSV-LRTD due ...

GSK’s Arexvy—which became the industry’s first FDA-approved RSV shot in May 2023—was greenlit for use in adults aged 50 to 59 in June 2024. On Thursday, GSK unveiled Phase IIIb data showing that a ...